serum gastrin level by 1.5-2-fold, which has raised concerns over whether hypergastrinemia resulting from long-term use of PPI may have adverse effects on the gastrointestinal tract [2] . Although no obvious neoplastic change was found in the gastric mucosa, an increase in enterochromaffin-like cells and fundic gland polyps was reported [3] . Numerous studies have suggested that the proliferative effect of hypergastrinemia may also affect the mucosa of the small intestine and colon [1, [3] [4] [5] . Patients with hypergastrinemia as a result of Zollinger-Ellison syndrome have a higher colonic proliferation index [1] . Interestingly, in some case-control studies, the prevalence of hypergastrinemia was higher in patients with colon cancer than in the control subjects. Because of the possible link between hypergastrinemia and colonic adenomatous polyps or colon cancer, it is likely that hypergastrinemia is mitogenic to human colon mucosa, and promote colonic carcinogenesis [6] [7] [8] [9] [10] [11] . Conversely, gastrin gene expression was observed in most colon cancer cell lines and in primary colorectal carcinoma [7, 8, 12] . In animal models, exogenous gastrin or hypergastrinemia induced by high-dose PPI increased the proliferation of normal colonic mucosa [13] . Although the US Food and Drug Administration has approved the long-term use of PPI in patients with reflux esophagitis, few studies have investigated the effect of PPI-induced hypergastrinemia on the colonic mucosa or the incidence of colonic adenomatous polyps. The aim of this study was to investigate whether PPI-induced hypergastrinemia was associated with gastrointestinal tract polyps, particularly colonic adenomatous polyps.
METHODS
This cross-sectional study was carried out at Kaohsiung Medical University Hospital, Taiwan. All patients and controls were recruited from our Digestive Endoscopy Center. This study was approved by the ethics committees of our institutional review board.
Patients
Between January 2007 and August 2007, a total of 259 subjects were enrolled in this study. These subjects underwent esophagogastroduodenoscopy (EGD) and colonoscopy. Exclusion criteria included incomplete colonoscopy examination, inadequate bowel preparation, inflammatory bowel disease, newly diagnosed gastrointestinal malignancy, and familial colon polyposis. Subjects with hypergastrinemia induced by conditions other than PPI use were excluded, including previous gastric surgery, pernicious anemia, Zollinger-Ellison syndrome, acromegaly, and pheochromocytoma. Medical records were reviewed, including history of chronic diseases and medication history including PPIs, non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. An uninterrupted period of PPI prescription of 2 months and 6 months was defined as continuous and long-term PPI use, respectively.
Serological test
Five milliliters of fasting blood was taken for plasma gastrin examination. The gastrin level was estimated by a radioimmunoassay.
Endoscopy
EGD was performed to evaluate gastric lesions. Helicobacter pylori infection status was examined by a rapid urease test. Gastric polyps were sampled by biopsy for histological examination. Pan-colonoscopy was performed after a complete bowel preparation with sodium phosphate. Detailed information was recorded for all polypoid lesions, including size and location (cecum, ascending colon, transverse colon, descending colon, and rectosigmoid colon). Biopsy was obtained for histological examination.
Statistical analysis
Qualitative parameters were analyzed using the χ 2 test and Fisher's exact two-sided tests. Analysis of variance was performed to compare the variations between the patient and control groups. A p value of < 0.05 was considered statistically significant. Data were analyzed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 259 subjects were included in this study, and all of them underwent EGD and colonoscopy. A total of 122 patients used PPIs for an average duration of 21.89 months (range, 1-97 months) and 91.8% used PPIs for more than 6 months. The control group who had no history of PPI or H2-blocker use comprised
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137 patients. The demographic data for patients in both groups are shown in Table 1 . The PPI users were older than the non-PPI users, because older patients often show more co-morbidities, including peptic ulcer disease, reflux esophagitis, arthropathy, and cardiovascular disease.
The prevalence of H. pylori infection was lower in both groups compared with general population because most of these patients had previously received H. pylori eradication therapy for peptic ulcer disease, particularly in the PPI user group. Furthermore, most of the patients in the PPI user group had received continuous PPI treatment, which affected the accuracy of the rapid urease test for H. pylori infection and provided some false-negative results.
The average gastrin level was 121.8 ρg/mL and 56.8 ρg/mL in the PPI group and the non-PPI group, respectively (p < 0.001) ( Figure 1 ). The prevalence of gastric polyps was higher in the PPI group than in the non-PPI group (65.6% vs. 37.2%; p < 0.001) ( Table 2) . By contrast, the prevalence of colon polyps was comparable in both groups (57.4% vs. 51.8%) ( Table 3) . Although female sex, gastrin level, PPI use, and negative H. pylori infection were associated with gastric polyps, only female sex and PPI use were significant risk factors in multivariate analysis (Table 2) . We also found that longer duration of PPI use was associated with higher incidence of gastric polyps ( Figure 2 ). By contrast, male sex, age, and history of colonic adenomas were associated with colon polyps, and age was the only significant risk factor in multivariate analysis (Table 3) .
We further analyzed the histological type of gastric polyps and colon polyps (Table 4) . Fundic gland polyps were the most prevalent gastric polyps and *Data presented as mean ± standard deviation or n (%). † Included inflammatory polyps, hyperplasia polyps, and fundic gland polyps; ‡ included inflammatory polyps, hyperplasia polyps, adenomatous polyps; PPI = proton pump inhibitor; NSAID = nonsteroidal anti-inflammatory drugs; COX = cyclooxygenase. *Data presented as n or mean ± standard deviation; Colon polyps included inflammatory polyps, hyperplasia polyps and adenomatous polyp; † multivariate analysis with adjusted OR for sex (male vs. female), age (continuous) and history of colon adenoma (yes vs. no). OR = odds ratio; CI = confidence interval; PPI = proton pump inhibitor; NSAID = non-steroidal anti-inflammatory drugs; COX = cyclooxygenase.
To exclude the possibility of underestimation, we found that, of the 259 patients included in this study, 165 patients had undergone colonoscopy in our hospital at least once, including 97 patients in the PPI group and 68 patients in the non-PPI group (Table 5) . The average number of previous colonoscopy examinations was 2.36 in the PPI group and 2.09 in the control group. There was no difference in the prevalence of colonic adenomas between the two groups, even in patients with history of colonic adenoma.
DISCUSSION
PPIs are powerful inhibitors of acid secretion and induce hypergastrinemia [2, 14] . Although the safety concerns over PPI-induced hypergastrinemia have been demonstrated in many studies, and are well reviewed [3, 15] , few studies have investigated the long-term effect of hypergastrinemia on colon mucosa. Meanwhile, the effect of hypergastrinemia on the incidence of colorectal adenomatous polyps remains controversial [10, 11, 16, 17] .
In animal models, hypergastrinemia has been implicated as a risk factor for colon cancer. Gastrin may induce proliferation during intestinal crypt regeneration following chemical or radiation injury [4] . Omeprazole-induced hypergastrinemia was shown to increase the number of small intestinal adenomas in APC min-/+ mice [13] . However, in this study, the gastrin level was 6-10-fold higher than that in the normal population and the effect of hypergastrinemia may be amplified. In humans, relatively few studies have examined the effect of hypergastrinemia on colon mucosa, particularly PPI-related hypergastrinemia. Two studies based on patients with ZollingerEllison syndrome showed that hypergastrinemia increased the rate of colonic proliferation but not the prevalence of adenomas [1, 18] . However, these studies did not describe the distribution of colonic adenomas and or provide longitudinal follow-up with colonoscopy. Another study analyzed 10 patients with autoimmune gastritis and six patients with ZollingerEllison syndrome, and all of them had undergone proctoscopy. This study showed that endogenous hypergastrinemia enhanced the proliferation of colorectal mucosa. However, it is unwise to over-interpret the results obtained in the rectum [5] . Two large population-based studies in Europe revealed that longterm PPI therapy (> 5 years) was not associated with increased risk of colon cancer. Unfortunately, these studies did not report the results of the colonoscopy examination, precancerous evaluation or the gastrin level [19, 20] . In our study, hypergastrinemia was two-fold higher in the PPI group than in the non-PPI group. The prevalence of gastric polyps was higher, particularly fundic gland polyps, in the PPI group. Our results are consistent with those of previous studies [21] [22] [23] . Moreover, we evaluated the long-term effect of PPI on colon mucosa in patients who had used PPIs for over 6 months. Overall, the prevalence of adenoma was similar in both groups. Our results are consistent with the results from population-based studies, suggesting that 20-40% of patients have prevalent colonic adenomas. We also found that neoplastic changes (tubulovillus adenoma, large adenoma, and high-grade dysplasia) were not associated with hypergastrinemia, regardless of the history of colonic adenoma. More importantly, our results reveal an important implication, that follow-up colonoscopy for colonic adenomas may be adequate for PPI users [24, 25] .
However, there are several weaknesses of our study. Selection bias may present in the patients who visited our hospital for their first colonoscopy. Patients who had undergone colonoscopy more than twice may be more relevant for evaluating the effect of hypergastrinemia between PPI users and non-PPI users. A huge variation in fasting gastrin level was noted among the PPI users. Many reasons may be attributed for this, including age, atrophic gastritis, blood sampling time and individual differences. One of the limitations of our study was the lack of longitudinal analysis of the gastrin level and assessment of gastrointestinal polyps before and after PPI use. These problems were also encountered in other studies. More studies are needed to clarify the association between long-term PPI use and effects on colonic mucosa.
In conclusion, our study showed that PPI users are prone to have gastric polyps, including fundic gland polyps. However, long-term use of PPIs was not associated with increased prevalence of colon polyps, irrespective of history of colonic adenoma. We also showed no carcinogenic effect of PPI use on the stomach and colon.
